12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erivedge vismodegib: Phase II data

Interim data from 17 evaluable patients in a single-arm, open-label, French Phase II trial showed that once-daily 150 mg oral vismodegib led to 4 cases of stable disease at 6 months, meeting the criteria for continued enrollment. Vismodegib was well tolerated. The trial, which has enrolled 40 patients, is being conducted...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >